Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AnHeart Therapeutics

AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics and Innovent Announce China’s NMPA Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics and Foundation Medicine Announce Collaboration to Develop Tissue-Based and Liquid-Based Companion Diagnostics for Taletrectinib, a ROS1 Inhibitor
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Expands U.S. Leadership With Development and Commercial Leads
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Announces Exclusive License Agreement With Nippon Kayaku for Taletrectinib in Japan
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics’ Investigational Medicine Taletrectinib Shrank Tumors in More Than 90 Percent of People With ROS1-Positive Non-Small Cell Lung Cancer Who Were ROS1 TKI Naïve in Global Pivotal TRUST-II Trial
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Appoints Charlotte Arnold as Chief Corporate Affairs Officer
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Announces Initiation of Global Phase 2 Trial Evaluating Safusidenib for IDH1-Mutant Glioma
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Appoints Edward Lang Jr. as Chief Business Officer
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Presents Updated Efficacy and Safety of Taletrectinib in Patients with ROS1-Positive Non–Small Cell Lung Cancer
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Announces Oral Presentation at the European Lung Cancer Congress (ELCC) 2023
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Announces Publication of Taletrectinib Global Phase 2 Clinical Trial (TRUST-II) Design in Future Oncology
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Receives FDA Clearance of IND Application to Initiate Global Phase 2 Study of Safusidenib in Glioma
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Expands US Team with Appointments in Clinical Research and Medical Affairs
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics and NewG Lab Therapeutics Receive Orphan Drug Designation in Korea for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics to Present Poster and Host Investigator Meeting at WCLC 2022
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Receives FDA Breakthrough Therapy Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Appoints Dr. Shuanglian (Lian) Li as Chief Medical Officer (US)
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1 Inhibitor) at ASCO 2022
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics to Present at Upcoming Investor and Industry Conferences
From ANHEART THERAPEUTICS
Via Business Wire
AnHeart Therapeutics Announces Presentation at the European Lung Cancer Congress (ELCC) 2022
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Appoints Prof. Andrés Cervantes to Scientific Advisory Board
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Raises $61 Million in Oversubscribed Series B Financing to Advance Precision Oncology Pipeline
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Appoints Hua Zheng, M.D, Ph.D, as SVP, Head of Global Regulatory Affairs
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Announces First Patient Dosed in Global Phase 2 TRUST-II Study for Taletrectinib in ROS1 Fusion-Positive Lung Cancer
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Launches Study to Evaluate AXL inhibitor AB-329 in Metastatic Breast Cancer
From AnHeart Therapeutics
Via Business Wire
AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
From AnHeart Therapeutics
Via Business Wire
AnHeart Therapeutics Announces Formation of Scientific Advisory Board
From AnHeart Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.